Clinical Trial

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated April 7, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2021-04-14; most recent amendment 2026-04-06.
Status change: Recruiting → Active, Not Recruiting 2025-07-14
Status change: Not Yet Recruiting → Recruiting 2024-03-27
Trial Details
NCT Number NCT04850118
Lead Sponsor Beacon Therapeutics
Conditions X-Linked Retinitis Pigmentosa
Enrollment 85 participants
Start Date 2024-03-14
Primary Completion 2026-06-30 (estimated)
Study Completion 2031-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-07